الفهرس 
Prostate AnatomyOnly 14 pages are availabe for public view
 |  | from | 128 |  |  |
| | | from | 128 | | |
Abstract
Prostate cancer (PCa) is rated the second most common cancer and sixth leading cause of cancer deaths among men globally. Androgen deprivation therapy (ADT) is the most important primary treatment for locally advanced or metastatic prostate cancer. However, due to the limited curative effect of a single treatment of ADT, combined therapy strategies are usually indicated. Although nearly all prostate cancer patients initially respond to ADT, almost all patients with hormone-sensitive prostate cancer(HSPC) progress to castration-resistant prostate cancer (CRPC) after several years of ADT. Currently, however, there is no unequivocal prediction model about the time of progression to CRPC.Prostate-specific antigen (PSA) has widely been accepted as a critical biomarker of the progression of prostate cancer during ADT, with some studies having reported that lower PSA nadir and longer time to PSA nadir (TTN) to be independent risk factors for a shorter time of progression to CRPC.This retrospective multivariate descriptive analysis study aimed to identify clinical predictive factors influencing the initial response to Androgen deprivation therapy and correlated to shorter time to castration resistance for metastatic prostate cancer.This study included 100 patients with metastatic prostatic cancer who initially treated by androgen deprivation therapy at the department of Clinical Oncology, Tanta University from 2006 to 2018. Patients with brain metastasis, unstable liver diseases, or inflammatory diseases were excluded from this study All patients were subjected to full history taking and clinical examination, and investigations as Prostate-specific antigen (PSA) baseline level, Bone and visceral metastasis were diagnosed by bone scan, magnetic resonance imaging of the pelvis, and computed tomography of the chest and abdomen